Cerebral haemorrhage in the patient with atrial fibrillation: do we employ the direct oral anticoagulants without waiting too long? [0.03%]
房颤患者脑出血后的直接口服抗凝药物治疗宜早不宜迟？
Gloria Vassiliki&#x; Coutsoumbas,Giuseppe Di Pasquale
Gloria Vassiliki&#x; Coutsoumbas
Intracranial haemorrhage (ICH) is the most feared haemorrhagic complication of oral anticoagulant therapy (OAT), although the risk is significantly lower with direct oral anticoagulants (DOACs) compared with warfarin. Intracranial haemorrha...
Antonio Mangieri,Antonio Colombo
Antonio Mangieri
Tricuspid regurgitation (TR) is common both in patients with left side valvular heart disease and in patients with permanent atrial fibrillation and is associated with increased mortality, morbidity, and an increased risk of hospitalization...
Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction [0.03%]
胰高血糖素样肽-1受体激动剂在肥胖和射血分数保留型心力衰竭中的作用
Pier Luigi Temporelli
Pier Luigi Temporelli
Heart failure with preserved ejection fraction (HFpEF) currently represents the majority of all heart failure cases in the community. Glucagon-like peptide-1 agonists represent a class of medications used to treat type 2 diabetes mellitus a...
Unlocking the enigma: decoding premature ventricular complexes for effective clinical assessment and risk management [0.03%]
破解谜团：解码早搏以进行有效的临床评估和风险管理
Leonardo Calo&#x;,Mario Tatangelo,Germana Panattoni et al.
Leonardo Calo&#x; et al.
The identification of ventricular premature complexes during a cardiological evaluation necessitates the implementation of diagnostic processes aimed at discerning the clinical context that may predispose individuals to a high risk of sudde...
Eliminate LDL cholesterol after heart attack … but only for a while [0.03%]
心脏病发作后降低坏胆固醇……但效果只能维持一段时间
Francesco Prati,Flavio Giuseppe Biccirè,Emanuele Sammartini et al.
Francesco Prati et al.
There is a clear demonstration of the inverse linear correlation between LDL cholesterol levels and clinical benefit. However, the timing of the action of lipid-lowering drugs is not clear. According to animal studies with recombinant lipop...
Efficacy of cryoablation in atrial fibrillation: comparison with antiarrhythmic therapy [0.03%]
冷冻消融治疗房颤的有效性与抗心律失常药物的比较研究
Silvia Magnani,Riccardo Cappato
Silvia Magnani
Atrial fibrillation (AF) represents the most common arrhythmia in clinical practice, characterized by irregular atrial electrical activity originating mainly in and around the pulmonary veins. This condition can manifest itself symptomatica...
Myocardial viability on trial [0.03%]
心肌活力受考验
Leonardo Bolognese,Matteo Rocco Reccia
Leonardo Bolognese
The concept of myocardial viability is usually referred to areas of the myocardium, which show contractile dysfunction at rest and in which contractility is expected to improve after revascularization. The traditional paradigm states that a...
Moderate aortic stenosis in the dysfunctional ventricle: should it be treated? [0.03%]
中度主动脉瓣狭窄合并心室功能不全时是否需要进行干预治疗？
Edoardo Sciatti,Alice Calabrese,Vincenzo Duino et al.
Edoardo Sciatti et al.
Moderate aortic stenosis is associated with a worse prognosis than milder degrees. Pathophysiologically, this condition in a dysfunctional ventricle could lead to a further mechanism of haemodynamic worsening, so its treatment should lead t...
The new 2023 ESC guidelines for the management of cardiomyopathies: a guiding path for cardiologist decisions [0.03%]
2023年欧洲心肌病管理指南解读——心肌病诊治的“心灵之路”
Maurizia Grasso,Davide Bondavalli,Viviana Vilardo et al.
Maurizia Grasso et al.
In the ESC 2023 guidelines, cardiomyopathies are conservatively defined as 'myocardial disorders in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease,...
The role of sodium-glucose co-transporter 2 inhibitors in myocardial infarction: available evidence and future perspectives [0.03%]
钠葡萄糖共转运体2抑制剂与心肌梗死：现有证据和未来展望
Giovanni Amedeo Tavecchia,Elena Gualini,Alice Sacco et al.
Giovanni Amedeo Tavecchia et al.
There is an unmet need for new treatment options for patients with acute myocardial infarction (AMI) as progress in patients' outcomes has plateaued over the past 15 years. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrate...